Do different populations of rectal cancer exist?

Multidisciplinary Management of Rectal Cancer: Questions and Answers

Volumn 9783642250057, Issue , 2012, Pages 49-55

  Valentini, Vincenzo ^a,b   Cellini, Francesco ^c   Barba, Maria Cristina ^a,b   Van Stiphout, Ruud ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949178864     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-25005-7_6     Document Type: Chapter

References (13)

1. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533-543
2. ® Rectal Cancer Treatment. Bethesda, MD: National Cancer Institute. (2011) http://cancer.gov/cancertopics/pdq/treatment/rectal/HealthProfessional
3. Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC et al (2011) Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 29:3163-3172
4. Wang Y, Cummings B, Catton P et al (2005) Primary radical external beam radiotherapy of rectal adenocar-cinoma: long term outcome of 271 patients. Radiother Oncol 77:126-132
5. Mohiuddin M, Ahmad N, Marks G (1993) A selective approach to adjunctive therapy for cancer of the rectum. Int J Radiat Oncol Biol Phys 27(4):765-772
6. Schwaab J, Horisberger K, Ströbel P (2011) Expression of transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemo-radiotherapy. BMC Cancer 11:363
7. Lammering G, Buijsen J (2012) What biochemical and molecular biological factors have greater relevance to treatment decisions? In: Multidisciplinary management of rectal cancer-questions and answers
8. Valentini V, van Stiphout R, Lammering G et al 2-Year Disease Free vs Pathological Complete Response as a Surrogate Endpoint by using Pooled Data of Randomized Trials for Locally Advanced Rectal Cancer. In Press
9. Sargent D, Shi Q, Yothers G (2011) Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropy-rimidines with or without oxaliplatin or irinotecan: data from 12, 676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47(7):990-996, Epub 2011 Jan 21
10. Valentini V, Coco C, Picciocchi A (2002) Does down-staging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53(3):664-674
11. Capirci C, Valentini V, Cionini L (2008) Prognostic value of pathologic complete response after neoadju-vant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 72(1):99-107, Epub 2008 Apr 11
12. Sebag-Montefiore D, Bujko K, Valentini V (2009) Rectal cancer multidisciplinary management: evidences and future landscape. Radiother Oncol 92(2):145-147, Epub 2009 Jul 10
13. van Stiphout R, Roelofs E, Dekker A (2012) How to share data and promote a rapid learning health medicine? In: Multidisciplinary management of rectal cancer-questions and answers